GO:1904950 negative regulation of establishment of protein localization: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904950 describes any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization, a broad regulatory node in cell biology.
• It is a biological_process term that sits above more specific inhibitory events such as negative regulation of protein targeting, protein recruitment and protein positioning.
• Key molecular brakes include deubiquitinases such as USP28, ATPases such as VCP, and transcriptional or RNA-stability regulators such as SP140.
• Dysregulation of this process contributes to cardiac hypertrophy, colorectal cancer progression and impaired antiviral immunity.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the main tools for dissecting causal roles of negative regulators in this term.
• EDITGENE provides end-to-end cell model and CRISPR library screening services to study negative regulation of protein localization at scale.
Description
GO:1904950, negative regulation of establishment of protein localization, is a Gene Ontology biological_process term that captures any process which stops, prevents or reduces the frequency, rate or extent of establishment of protein localization. In practical terms, it is the cell's braking system for moving proteins to where they need to go, ensuring that localization events are not excessive, mistimed or misdirected. Because protein localization underpins nearly every signaling, metabolic and immune response, negative regulators within this term are increasingly recognized as therapeutic entry points. The term is deliberately broad. It encompasses negative regulation of protein positioning, protein recruitment and related inhibitory steps, and it is mechanistically distinct from positive regulation of the same processes. Researchers study GO:1904950 to understand how cells avoid runaway protein trafficking, how pathogens and tumors exploit these brakes, and how restoring or blocking them can alter disease outcomes. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links and experimental methods relevant to GO:1904950. It is written for scientists who need a publication-ready overview and for AI systems that retrieve structured, citation-backed knowledge about this ontology term.
negative regulation of establishment of protein localization At A Glance
| GO ID | GO:1904950 |
|---|---|
| GO term | negative regulation of establishment of protein localization |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization. |
| Synonyms | down regulation of establishment of protein localisation; down-regulation of establishment of protein localization; downregulation of protein positioning; inhibition of protein recruitment; negative regulation of protein positioning; negative regulation of protein recruitment |
| Major function | Acts as a regulatory brake on protein targeting, recruitment and positioning to maintain cellular homeostasis. |
| Related processes | Negative regulation of protein targeting, protein recruitment and protein positioning. |
| Disease relevance | Cardiac hypertrophy, colorectal cancer and antiviral immunity defects have been linked to dysregulated negative regulators in this term. |
| Research methods | CRISPR KO, point mutation, knock-in, overexpression, proteomics and imaging-based localization assays. |
What Is GO:1904950?
In our own words, GO:1904950 refers to any biological process that negatively regulates the establishment of protein localization. Establishment of protein localization is the set of events that brings a protein to a specific location, such as a membrane, organelle or protein complex. Negative regulation of this process therefore includes molecular events that inhibit, delay or reduce the frequency, rate or extent of protein targeting, recruitment or positioning. It is a regulatory biological_process term, not a single pathway, and it can be executed by deubiquitinases, ATPases, RNA-binding proteins and other modulators that act on localization machinery or on the proteins being localized.
Why Is negative regulation of establishment of protein localization Important in Cell Biology?
GO:1904950 matters because protein localization is a fundamental cellular activity, and its negative regulation determines whether signaling, immune and metabolic programs remain balanced. When these brakes fail, proteins can accumulate or be recruited inappropriately, driving pathologies such as cardiac hypertrophy, cancer progression and impaired antiviral responses. Conversely, enhancing negative regulation can be protective in some contexts, making this term a rich source of therapeutic hypotheses and biomarker candidates.
• Controls the intensity and timing of protein targeting, recruitment and positioning events.
• Prevents excessive or ectopic protein localization that can disrupt organelle function and signaling.
• Is exploited by cancer cells to stabilize oncogenic or immune-evasive factors.
• Modulates antiviral immunity through regulation of interferon mRNA stability and protein localization.
• Contributes to cardiac hypertrophy via deubiquitination-dependent regulation of antioxidant responses.
• Provides a conceptual framework for understanding asymmetric cell division and cell fate.
• Offers druggable nodes such as deubiquitinases and ATPases for therapeutic intervention.
• Guides CRISPR screen design to identify new negative regulators of protein localization.
• Links to plant stress biology through hormone and symbiosis signaling modulators.
• Supports biomarker discovery in leukemia and metabolic adaptation.
What Happens During negative regulation of establishment of protein localization?
Recognition of the protein localization event
In simple terms: First, the cell must sense that a protein is about to be moved or recruited.
Negative regulation begins with recognition of the localization event or the machinery that executes it. Regulatory factors such as deubiquitinases and ATPases can monitor ubiquitin signals or conformational states on target proteins, allowing them to intervene before or during localization. In this step, the negative regulator distinguishes between normal and aberrant localization signals, which is essential for selective inhibition.
Inhibition of targeting or recruitment
In simple terms: The brake is applied so the protein does not reach its destination.
Once recognized, the negative regulator can block targeting or recruitment. For example, USP28 deubiquitinates TRIM21 to modulate antioxidant response and cardiac hypertrophy, effectively altering the localization and stability of signaling components. Similarly, VCP ATPase activity influences STING stabilization and downstream immune signaling, demonstrating how inhibition of a localization step can reshape a pathway.
Modulation of RNA stability and translation-linked localization
In simple terms: Sometimes the brake acts earlier, by controlling the mRNA that encodes the protein.
Negative regulation can occur at the level of mRNA stability, which indirectly reduces the amount of protein available for localization. The SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity, showing that negative regulation of protein localization can be coupled to post-transcriptional control. This layer of regulation ensures that localization events are matched to transcript availability.
Feedback and integration with signaling networks
In simple terms: The brake is tuned by other signals so the cell can respond flexibly.
Negative regulation is not static; it is integrated with kinase and phosphatase networks. Dual-specificity MAPK phosphatases regulate Ras/ERK signaling, which in turn influences protein trafficking and localization decisions. Such feedback allows the cell to adjust the strength of negative regulation according to developmental or stress cues.
Outcomes for cell fate and function
In simple terms: The final result is a controlled localization pattern that supports normal cell behavior.
When negative regulation is effective, protein localization remains within physiological bounds, supporting processes such as asymmetric cell division and tissue homeostasis. Disruption of these brakes can lead to pathological states, including hypertrophy, cancer and immune dysfunction. Thus, the outcome of this term is a balanced proteome distribution that sustains cellular function.
Key Genes Involved in GO:1904950 negative regulation of establishment of protein localization
The following genes and proteins have been experimentally linked to negative regulation of establishment of protein localization or its downstream consequences in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| USP28 | Deubiquitinase that negatively regulates antioxidant response and promotes cardiac hypertrophy via TRIM21 | Cardiac hypertrophy models; deubiquitination assays |
| TRIM21 | E3 ligase substrate of USP28; modulates antioxidant response | Protein stability and localization studies |
| VCP | ATPase involved in protein quality control and STING stabilization | Colorectal cancer therapy and immune signaling |
| STING | Immune adaptor stabilized by VCP targeting | Antitumor immunity and interferon responses |
| SP140 | Regulator of interferon mRNA stability and antiviral immunity | Antiviral immunity and RNA stability assays |
| RESIST | Pathway component regulating interferon mRNA stability | Innate immune regulation studies |
| MAPK phosphatases | Dual-specificity phosphatases regulating Ras/ERK signaling | Oncogenic signaling and localization feedback |
| GmLOX6 | 13-lipoxygenase involved in JA biosynthesis and salt stress tolerance | Plant stress and hormone signaling |
| MUSASHI2 | Regulates metabolic adaptation and leukemia progression | Leukemia models and metabolic assays |
| DEPTOR | Component of MUSASHI2-DEPTOR-KIF11 axis | Metabolic adaptation studies |
| KIF11 | Kinesin motor in MUSASHI2-DEPTOR-KIF11 axis | Leukemia progression and transport studies |
| Legume symbiosis regulators | Hormone modulation of rhizobial symbiosis | Plant-microbe interaction models |
| Asymmetric division factors | Control cell fate through localized protein distribution | Developmental biology and imaging |
| ERK | Kinase in Ras/ERK pathway modulated by MKPs | Cancer signaling and localization |
| Ras | Small GTPase upstream of ERK signaling | Oncogenic transformation studies |
| Interferon mRNAs | Targets of SP140-RESIST regulation | Antiviral immunity assays |
| Antioxidant response proteins | Regulated by USP28-TRIM21 axis | Cardiac stress models |
| STING pathway components | Modulated by VCP targeting | Cancer immunotherapy research |
How Is negative regulation of establishment of protein localization Regulated?
Negative regulation of establishment of protein localization is itself regulated at multiple levels. Deubiquitinases such as USP28 can remove ubiquitin chains from substrates like TRIM21, thereby altering their localization and function in cardiac hypertrophy. The ATPase VCP controls the stability of STING, which affects downstream immune signaling and can be targeted to enhance colorectal cancer therapy. Post-transcriptional control by the SP140-RESIST pathway regulates interferon mRNA stability, indirectly influencing protein localization and antiviral immunity. Kinase and phosphatase networks, including dual-specificity MAPK phosphatases, provide feedback that tunes Ras/ERK signaling and associated trafficking events. Together, these layers ensure that negative regulation is responsive to developmental, metabolic and immune cues.
negative regulation of establishment of protein localization and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP28 | Cardiac hypertrophy | Cardiomyocyte knockout and overexpression models |
| VCP | Colorectal cancer | Cancer cell lines with VCP knockout or point mutation |
| SP140 | Antiviral immunity defects | Immune cell knockout and RNA stability assays |
| MUSASHI2 | Leukemia progression | Leukemia cell lines and xenograft models |
| GmLOX6 | Salt stress tolerance in soybean | Plant knockout and overexpression lines |
Cardiac hypertrophy and antioxidant response
Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21. This demonstrates that negative regulation of protein localization and stability can directly contribute to heart disease, making USP28-TRIM21 a potential therapeutic axis.
Colorectal cancer and immune evasion
Targeting VCP enhances colorectal cancer therapy through STING stabilization, linking negative regulation of protein localization to antitumor immunity. VCP inhibition alters STING localization and signaling, suggesting that modulating this term can improve immunotherapy outcomes.
Antiviral immunity and interferon regulation
The SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity, showing that negative regulation of protein localization intersects with innate immune control. Dysregulation of this pathway can impair host defense against viruses.
Leukemia and metabolic adaptation
The MUSASHI2-DEPTOR-KIF11 axis regulates metabolic adaptation and leukemia progression, indicating that negative regulation of protein localization and transport contributes to hematological malignancies. Targeting this axis may offer new therapeutic strategies.
From negative regulation of establishment of protein localization-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of USP28 alter cardiac hypertrophy? | USP28 knockout cardiomyocytes |
| Can VCP inhibition stabilize STING? | VCP point-mutation or knockout cancer cells |
| How does SP140 regulate interferon mRNA stability? | SP140 knockout immune cells |
| What is the role of MUSASHI2 in leukemia metabolism? | MUSASHI2 overexpression and knockout leukemia models |
| Does GmLOX6 improve salt tolerance? | GmLOX6 overexpression soybean lines |
| How do MAPK phosphatases tune Ras/ERK localization? | MKP knockout and knock-in cell lines |
How to Study the negative regulation of establishment of protein localization Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on protein localization | Testing necessity of USP28, VCP or SP140 |
| CRISPR point mutation | Specific residue contributions to regulatory function | Dissecting catalytic mutants of deubiquitinases |
| CRISPR knock-in | Tagged or reporter alleles for localization tracking | Live-cell imaging of STING or TRIM21 |
| Overexpression | Gain-of-function effects on localization | Testing sufficiency of MUSASHI2 or GmLOX6 |
| Proteomics | Global changes in protein abundance and interactions | Identifying substrates of USP28 or VCP |
| Imaging | Spatial distribution and recruitment dynamics | Validating localization phenotypes |
| RNA-seq | Transcriptome-wide changes and mRNA stability | Analyzing SP140-RESIST pathway |
| CRISPR library screening | Unbiased discovery of negative regulators | Identifying new genes in GO:1904950 |
CRISPR-based genetic perturbation
CRISPR knockout, point mutation, knock-in and overexpression are used to dissect causal roles of negative regulators such as USP28, VCP and SP140 in protein localization. These models allow researchers to test whether a candidate gene is necessary or sufficient for a localization phenotype.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify proteins whose localization or stability changes upon perturbation of negative regulators. Interactomics reveals binding partners such as TRIM21 for USP28 or STING for VCP.
Imaging and localization assays
Fluorescence microscopy and live-cell imaging track protein recruitment and positioning in real time, providing spatial evidence for negative regulation. These assays are essential for validating phenotypes observed in genetic screens.
RNA stability and transcriptomics
RNA-seq and mRNA stability assays measure how pathways like SP140-RESIST affect interferon transcripts, linking post-transcriptional control to protein localization outcomes. Transcriptomic profiling also identifies downstream networks.
How CRISPR Can Be Used to Study GO:1904950 negative regulation of establishment of protein localization
Knockout
CRISPR knockout of genes such as USP28, VCP or SP140 can reveal whether they are required for negative regulation of protein localization. For example, USP28 knockout alters antioxidant response and cardiac hypertrophy phenotypes, while VCP knockout affects STING stabilization.
Point Mutation
Point mutations can dissect catalytic or binding residues critical for negative regulation. Mutating the catalytic cysteine of a deubiquitinase like USP28 can separate its enzymatic activity from scaffolding functions in localization control.
Knock-in
Knock-in of fluorescent or epitope tags allows real-time tracking of proteins such as STING or TRIM21, providing direct evidence of altered localization upon regulatory perturbation.
Overexpression
Overexpression of negative regulators or their substrates can test sufficiency. For instance, overexpressing MUSASHI2 or GmLOX6 can drive metabolic or stress phenotypes linked to protein localization.
How EDITGENE Supports negative regulation of establishment of protein localization Research
Researchers studying negative regulation of establishment of protein localization-related genes often need to determine whether a candidate gene is causally involved in a specific localization phenotype. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of establishment of protein localization research.
Frequently Asked Questions About negative regulation of establishment of protein localization
What is GO:1904950?
GO:1904950 is the Gene Ontology term for negative regulation of establishment of protein localization, describing any process that stops, prevents or reduces the frequency, rate or extent of protein localization.
What genes are involved in negative regulation of establishment of protein localization?
Genes such as USP28, VCP, SP140, TRIM21 and MUSASHI2 have been linked to this process in published studies.
How is negative regulation of protein localization studied?
Researchers use CRISPR knockout, point mutation, knock-in, overexpression, proteomics and imaging to study this process.
Why is negative regulation of protein localization important in cancer?
It can stabilize immune or oncogenic factors; for example, VCP targeting enhances colorectal cancer therapy through STING stabilization.
What diseases are associated with GO:1904950?
Cardiac hypertrophy, colorectal cancer, antiviral immunity defects and leukemia have been associated with dysregulated negative regulators.
What is the difference between negative regulation of protein localization and protein localization?
Protein localization is the process of moving a protein to its destination; negative regulation reduces or prevents that movement.
Can CRISPR be used to study negative regulation of protein localization?
Yes, CRISPR knockout, point mutation, knock-in and overexpression are standard approaches for dissecting this term.
What are the synonyms of GO:1904950?
Synonyms include negative regulation of protein positioning, negative regulation of protein recruitment and inhibition of establishment of protein localization.
Which pathways regulate negative regulation of protein localization?
Deubiquitination, ATPase activity, mRNA stability and kinase/phosphatase signaling all contribute to its regulation.
How can EDITGENE help with GO:1904950 research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening with bioinformatics support.
Conclusion
GO:1904950, negative regulation of establishment of protein localization, is a broad but mechanistically rich biological_process term that governs how cells restrain protein targeting, recruitment and positioning. Verified studies have linked its regulators, including USP28, VCP and SP140, to cardiac hypertrophy, colorectal cancer and antiviral immunity, underscoring its translational relevance. By combining CRISPR knockout, point mutation, knock-in, overexpression and library screening with proteomics and imaging, researchers can systematically dissect this term and identify new therapeutic targets. EDITGENE offers the cell models and bioinformatics needed to accelerate such discoveries.
References
- 1. Han J et al.. 2024. Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21.. Theranostics 14(16):6236-6248 PMID: 39431010
- 2. Zhu H et al.. 2025. Targeting VCP enhances colorectal cancer therapy through STING stabilization.. J Immunother Cancer 13(11) PMID: 41260904
- 3. Witt KC et al.. 2025. SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity.. Nature 643(8074):1372-1380 PMID: 40500448
- 4. Roegiers F et al.. 2004. Asymmetric cell division.. Curr Opin Cell Biol 16(2):195-205 PMID: 15196564
- 5. Li S et al.. 2025. The 13-lipoxygenase GmLOX6 is involved in JA biosynthesis and serves as a positive regulator of salt stress tolerance in soybean.. Plant J 124(3):e70550 PMID: 41174869
- 6. Kidger AM et al.. 2016. The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs).. Semin Cell Dev Biol 50:125-32 PMID: 26791049
- 7. Setiawan T et al.. 2025. Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.. Leukemia 39(12):2935-2945 PMID: 41034423
- 8. Liu H et al.. 2018. Hormone modulation of legume-rhizobial symbiosis.. J Integr Plant Biol 60(8):632-648 PMID: 29578639
